|
KMID : 0360319930250030325
|
|
Journal of Korean Cancer Research Association
1993 Volume.25 No. 3 p.325 ~ p.333
|
|
|
Singnificance of Serum CA19-9, CA125, CEA and a-FP in Gastric Cancer
|
|
예호열
송선교/김홍진/심민철/권굉보
|
|
|
Abstract
|
|
|
Various tumor markers have been utilized to a gastric cancer mangement. But no ideal marker has been found yet.
To determine whether several tumor markers presently available could be utilized for the gastric cancer management the author conducted following study;
Serum CA19-9, CA-125, CEA and a-fetoprotein were measured in 288 gastric cancer patients before sugery, and at 3,6 and 12 months following surgery.
The blood level of each tumor marker was compared with clnincal stage of the gastric cancer and presence of postoperative recurence.
The positivity of each tumor marker to the stomach cancer was 29.6% with CA19-9, 22.4% with CA125, 13.6% with CEA, and 20.7% with a-FP.
Preoperative positivities of tumor marker were not correlated with stages, but the preoperative positivities were significantly higher at stage IV(p<0.05).
There was no correlation between depth of invasion and positivity of each tumor marker, but the positivites were significantly higher at T4 The positivities of CA19-9 and CA125 at T4 were 64.0% and 66.2%.
At the comsparison of tumor marker positivity and nodal status it was statistically not significant between No and N1 but it was significant between No and N2(p<0.05).
The preoperative positivities were significantly higher with presence of distant metastasis. In hepatic metastasis, the positivities of CA125 and CA19-9 were 63.6% and 54.5%, but positivity of a-fetoprotein was 41.7%.
In peritoneal dissemination the highest positivity was found to be 63.6% with CA125.
In conclusion, CA19-9 is the best tumor marker for stomach cancer at the determination of the advanced stage, presence of hepatic metastasis, and resectability. The CA19-9 and CA125 thought to be helpful markers in the detection of recurrences.
High
CFEA titer was frequently associated with an advanced stage or a hepatic recurrence.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|